SC 13G/A | 2024-02-14 | Avoro Capital Advisors LLC | Xenon Pharmaceuticals Inc. | 5,666,666 | 7.7% | EDGAR |
SC 13G/A | 2024-02-14 | DRIEHAUS CAPITAL MANAGEMENT LLC | Xenon Pharmaceuticals Inc. | 4,345,180 | 5.9% | EDGAR |
SC 13G/A | 2024-02-09 | FMR LLC | Xenon Pharmaceuticals Inc. | 5,655,922 | 7.6% | EDGAR |
SC 13G | 2024-02-08 | WELLINGTON MANAGEMENT GROUP LLP | Xenon Pharmaceuticals Inc. | 4,162,654 | 5.6% | EDGAR |
SC 13G/A | 2023-02-14 | Point72 Asset Management, L.P. | Xenon Pharmaceuticals Inc. | 1,178,324 | 1.9% | EDGAR |
SC 13G/A | 2023-02-14 | Avoro Capital Advisors LLC | Xenon Pharmaceuticals Inc. | 4,900,000 | 7.8% | EDGAR |
SC 13G/A | 2023-02-14 | BIOTECHNOLOGY VALUE FUND L P | Xenon Pharmaceuticals Inc. | 681,278 | 1.1% | EDGAR |
SC 13G/A | 2023-02-10 | DRIEHAUS CAPITAL MANAGEMENT LLC | Xenon Pharmaceuticals Inc. | 4,681,797 | 7.5% | EDGAR |
SC 13G/A | 2023-02-09 | FMR LLC | Xenon Pharmaceuticals Inc. | 4,690,829 | 7.5% | EDGAR |
SC 13G/A | 2022-03-21 | BIOTECHNOLOGY VALUE FUND L P | Xenon Pharmaceuticals Inc. | 2,295,557 | 4.4% | EDGAR |
SC 13G/A | 2022-02-14 | Point72 Asset Management, L.P. | Xenon Pharmaceuticals Inc. | 2,992,597 | 5.8% | EDGAR |
SC 13G/A | 2022-02-14 | BIOTECHNOLOGY VALUE FUND L P | Xenon Pharmaceuticals Inc. | 2,819,594 | 5.5% | EDGAR |
SC 13G | 2022-02-14 | DRIEHAUS CAPITAL MANAGEMENT LLC | Xenon Pharmaceuticals Inc. | 3,123,229 | 6.0% | EDGAR |
SC 13G/A | 2022-02-11 | Avoro Capital Advisors LLC | Xenon Pharmaceuticals Inc. | 4,985,000 | 9.7% | EDGAR |
SC 13G/A | 2022-02-11 | ORBIMED ADVISORS LLC | Xenon Pharmaceuticals Inc. | 631,000 | 1.2% | EDGAR |
SC 13G/A | 2022-02-10 | ADAGE CAPITAL PARTNERS GP, L.L.C. | Xenon Pharmaceuticals Inc. | 665,000 | 1.3% | EDGAR |
SC 13G/A | 2022-02-09 | FMR LLC | Xenon Pharmaceuticals Inc. | 3,910,017 | 7.6% | EDGAR |
SC 13G | 2021-10-28 | Point72 Asset Management, L.P. | Xenon Pharmaceuticals Inc. | 2,624,160 | 5.0% | EDGAR |
SC 13G/A | 2021-02-16 | BIOTECHNOLOGY VALUE FUND L P | Xenon Pharmaceuticals Inc. | 1,871,995 | 5.4% | EDGAR |
SC 13G/A | 2021-02-12 | Avoro Capital Advisors LLC | Xenon Pharmaceuticals Inc. | 2,800,000 | 8.0% | EDGAR |